
LamotriginevDispersible tablets
Form: Tablets(IR & ER)
Strength: XR: 25 mg, 50 mg, 100 mg, 200 mg; IR: 25 mg, 100 mg, 200 mg, 300 mg
Reference Brands: Lamictal, Lamictal XR(EU & US)
Category: Multiple sclerosis
Lamotrigine dispersible tablets, available as immediate-release (IR) and extended-release (ER), are approved in the US by the FDA and in the EU via EMA for epilepsy and bipolar disorder management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial data and manufacturing processes, while the EMA ensures compliance with regional safety and quality regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance facilitates timely approvals, supports safe use, and promotes worldwide availability of lamotrigine dispersible tablets, improving long-term patient care globally.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Tolterodine tablets/ Capsules(IR & ER)
Strength: IR: 1 mg, 2 mg; ER: 2mg, 4 mg
Form: Tablets/ Capsules(IR & ER)
Reference Brands: Detrol, Detrol LA(US & EU)
View Details Get EnquiryOxybutynin tstransdermal patch
Strength: 3.9 mg/24 hours
Form: transdermal patch
Reference Brands: Oxytrol, Oxytrol for Women(US & EU)
View Details Get EnquiryOxybutynin tablets
Strength: IR: 5 mg, 10 mg; ER: 5 mg, 10 mg
Form: Tablet(IR & ER)
Reference Brands: Ditropan, Oxybutynin XL(US)
View Details Get EnquiryDalfampridine
Strength: 10 mg
Form: Extended-Release tablets (XR)
Reference Brands: Ampyra(US)
View Details Get Enquiry